Search results
Results from the WOW.Com Content Network
The antiestrogen withdrawal syndrome is analogous to but less common and well-known than the antiandrogen withdrawal syndrome, a phenomenon in which paradoxical improvement in prostate cancer occurs upon discontinuation of antiandrogen therapy. [4]
Tamoxifen, sold under the brand name Nolvadex among others, is a selective estrogen receptor modulator used to prevent breast cancer in women and men. [13] It is also being studied for other types of cancer. [13] It has been used for Albright syndrome. [14] Tamoxifen is typically taken daily by mouth for five years for breast cancer. [14]
Tamoxifen is currently first-line treatment for nearly all pre-menopausal women with hormone receptor-positive breast cancer. [1] Raloxifene is another partial agonist SERM which does not seem to promote endometrial cancer , and is used primarily for chemoprevention of breast cancer in high-risk individuals, as well as to prevent osteoporosis ...
In a 1970 clinical trial, tamoxifen, which went by the name Nolvadex, was given to 60 breast cancer patients. This anti-estrogen drug had significantly shrunk the tumors while causing minimal side effects. [6] In 1988, she published an article on the history of the development of Tamoxifen. [7] Richardson was named on several patents. [8]
Toremifene is approved for the treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive or unknown-status tumors. [4] [6] This is its only approved use in the United States. [4] It shows equivalent effectiveness to tamoxifen for this indication.
Kate Middleton is opening up about the long-term side effects of her cancer treatment.. On Tuesday, Jan. 14, the Princess of Wales spoke with staff during a surprise visit to the Royal Marsden ...
"Boy Meets World" star Danielle Fishel is sharing an update on her breast cancer battle.. On Monday's episode of her "Pod Meets World" podcast, the actress, 43, revealed she is "officially done ...
Sivifene (A-007) was initially thought to be a SERM due to its structural similarity to tamoxifen but it was subsequently found not to bind to the estrogen receptor (ER). [8] Tesmilifene (DPPE; YMB-1002, BMS-217380-01) is also structurally related to tamoxifen but similarly does not bind to the ER and is not a SERM.